Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R. Black DM, et al. J Bone Miner Res. 2012 Feb;27(2):243-54. doi: 10.1002/jbmr.1494. J Bone Miner Res. 2012. PMID: 22161728 Free PMC article. Clinical Trial.
Fracture risk and zoledronic acid therapy in men with osteoporosis.
Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E. Boonen S, et al. N Engl J Med. 2012 Nov 1;367(18):1714-23. doi: 10.1056/NEJMoa1204061. N Engl J Med. 2012. PMID: 23113482 Free article. Clinical Trial.
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY. Devogelaer JP, et al. Rheumatology (Oxford). 2013 Jun;52(6):1058-69. doi: 10.1093/rheumatology/kes410. Epub 2013 Jan 30. Rheumatology (Oxford). 2013. PMID: 23365149 Clinical Trial.
Clinical risk factors for recurrent fracture after hip fracture: a prospective study.
Colón-Emeric CS, Lyles KW, Su G, Pieper CF, Magaziner JS, Adachi JD, Bucci-Rechtweg CM, Haentjens P, Boonen S; HORIZON Recurrent Fracture Trial. Colón-Emeric CS, et al. Calcif Tissue Int. 2011 May;88(5):425-31. doi: 10.1007/s00223-011-9474-4. Epub 2011 Feb 18. Calcif Tissue Int. 2011. PMID: 21331567 Clinical Trial.
Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW; HORIZON Recurrent Fracture Trial. Boonen S, et al. J Am Geriatr Soc. 2011 Nov;59(11):2084-90. doi: 10.1111/j.1532-5415.2011.03666.x. Epub 2011 Oct 21. J Am Geriatr Soc. 2011. PMID: 22091563 Clinical Trial.
36 results